Role of Co-trimoxazole in Severe COVID-19 Patients

Launched by BANGABANDHU SHEIKH MUJIB MEDICAL UNIVERSITY, DHAKA, BANGLADESH · Jul 13, 2020

Keywords

ClinConnect Summary

Coronavirus disease (COVID-19) caused by SARS-COV2, represents a highly transmissible and potentially fatal disease that is of great global public health concern at this moment. The pandemic situation in Bangladesh is also evolving rapidly with positive cases and deaths increasing each day. Epidemiological changes in COVID-19 infection should be monitored taking into account potential routes of transmission and subclinical infections, in addition to the adaptation, evolution, and virus spread among humans and possible intermediate animals and reservoirs. But till today there is no specific ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Diagnosed COVID-19 patients ( RT-PCR positive for COVID-19)
• • 2. Age \> 18 years
• • 3. Hypoxic respiratory failure (saturation \<90% on air at rest or increasing oxygen requirement)
• • 4. Chest examination findings of bilateral crackles on auscultation or chest x-ray showing bilateral infiltrates
• • 5. C-Reactive Protein \> 50mg/L
• Exclusion Criteria:
• • 1. Multi-organ failure
• • 2. Severe ARDS (requiring ventilator support on presentation in the form of invasive or non-invasive ventilation)
• • 3. Septic Shock
• • 4. Severe liver disease
• • 5. Acute Kidney Injury (where GFR\< 15 and plasma-sulfamethoxazoleconcentration cannot be monitored)
• • 6. Drug allergy/intolerance to co-trimoxazole / Sulphar sensitivity
• • 7. Pregnancy
• • 8. Already receiving Tocilizumab or convalescent therapy